Key Insights

Highlights

Success Rate

95% trial completion (above average)

Published Results

127 trials with published results (14%)

Research Maturity

602 completed trials (67% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.5%

31 terminated out of 894 trials

Success Rate

95.1%

+8.6% vs benchmark

Late-Stage Pipeline

14%

122 trials in Phase 3/4

Results Transparency

21%

127 of 602 completed with results

Key Signals

127 with results95% success31 terminated

Data Visualizations

Phase Distribution

635Total
Not Applicable (235)
Early P 1 (4)
P 1 (149)
P 2 (125)
P 3 (70)
P 4 (52)

Trial Status

Completed602
Unknown118
Recruiting65
Terminated31
Not Yet Recruiting29
Active Not Recruiting25

Trial Success Rate

95.1%

Benchmark: 86.5%

Based on 602 completed trials

Clinical Trials (894)

Showing 20 of 20 trials
NCT06214910Not ApplicableCompletedPrimary

ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa

NCT07735754Not Yet RecruitingPrimary

A Step Forward for Unraveling the Immune Mechanisms and Tools for Tuberculosis Spectrum Management

NCT01212003Recruiting

Training Protocol on the Natural History of Tuberculosis

NCT06253715Phase 3RecruitingPrimary

Shortened Regimen for Drug-susceptible TB in Children

NCT06739915Not ApplicableCompleted

Targeted Universal TB Testing With Simultaneous TPT Prescribing Among People Living With HIV in South Africa

NCT07018076RecruitingPrimary

Candidate Clinical Correlate of Prognostic Outcome for TB Study

NCT03896750Phase 1Completed

Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function

NCT07708779Phase 1RecruitingPrimary

A Phase I Study Investigating the Local Tolerability and Pharmacokinetics of Isoniazid (INH) Inhalation by Wet Nebulization in Patients With Tuberculosis

NCT06022146Phase 3RecruitingPrimary

A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)

NCT02906007Phase 1CompletedPrimary

Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV

NCT04311502Phase 2Terminated

Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

NCT06221488RecruitingPrimary

Testing Health Workers At Risk to Advance Our Understanding of TB Infection

NCT00164450Not ApplicableCompletedPrimary

TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection

NCT07687121Not Yet RecruitingPrimary

Shaping a Community-based Pathway to Improve TB Surveillance Among African and Hindustan Immigrants Experiencing Vulnerabilities

NCT04975737Phase 3Active Not RecruitingPrimary

Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac

NCT06751706Enrolling By InvitationPrimary

Detection of Mycobacterium Tuberculosis in Blood of TB Patients and Their Contacts in Uganda

NCT03266003Not ApplicableCompletedPrimary

An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment

NCT07677904Not Yet RecruitingPrimary

Tuberculosis Clinical Registry in Europe

NCT04926922CompletedPrimary

PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia

NCT07668479Not Yet RecruitingPrimary

Rifapentine-Based Shorter Regimens for Tuberculosis and TB Infection in Kazakhstan

Scroll to load more

Research Network

Activity Timeline